Member

Arnav Biotech


Arnav Biotech is an mRNA manufacturing and contract research company focused on developing high-quality, custom mRNA for therapeutic, vaccine, diagnostic, and agricultural applications. The company aims to support academic and industry scientists in developing mRNA-based therapeutics and vaccines through expert design and optimization.

Industries

biotechnology
health-care
life-science

Nr. of Employees

small (1-50)

Arnav Biotech

Arnav Biotech is currently seeking investment

Arnav Biotech is seeking a pre-seed investment in the range of 1m-5m

All Investment-seeking Members

Products

Pre-designed capped and polyadenylated mRNA for screening

Ready-to-use, fully capped and polyadenylated mRNA constructs intended for screening delivery formulations in vitro and in vivo.

Reporter mRNA (luminescent and fluorescent)

mRNA constructs encoding luciferase and fluorescent proteins optimized for rapid expression and use in transfection efficiency assays, whole-body imaging, and biodistribution studies.

Functional enzyme-encoding mRNA

mRNA constructs encoding functional enzymes (examples include recombinase and beta-galactosidase) for use in functional screening, reporter activation, selection marker removal, and imaging assays.

Multi-epitope-tagged mRNA constructs

mRNA constructs engineered to include multiple epitope tags to permit orthogonal detection and affinity purification using standard immunoassays and tag-based methods.

Expertise Areas

  • mRNA design and optimization
  • Custom mRNA manufacturing
  • mRNA purification and analytics
  • Process development and scale-up for mRNA
  • Show More (4)

Key Technologies

  • mRNA synthesis
  • Modified nucleoside incorporation
  • 5' capping methods
  • Poly(A) tail engineering
  • Show More (6)

Key People

Dr. Pooja M. Tiwari

Co-founder and CEO

LinkedIn

Investors

MassChallenge

Announced on 2023-07-26.


News & Updates

ARNAV Biotech has announced an exclusive license agreement with Alabama State University for a novel anti-respiratory syncytial virus (RSV) therapeutics, aiming to move the drug quickly to pre-IND and IND enabling studies.

Collaboration to develop a purification and analytical platform for the Arnav Biotech mRNA pipeline, leveraging Sartorius BIA Separations’ platforms for purification and analytics.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.